AC Immune (ACIU) Cash from Financing Activities (2015 - 2025)

AC Immune (ACIU) has reported Cash from Financing Activities for 10 consecutive years, with -$224879.8 the latest figure, recorded in Q4 2024.

• In Q4 2024, Cash from Financing Activities fell 100.49% year-over-year to -$224879.8; the TTM figure through Dec 2024 stood at $46.3 million (changed 0.26% YoY), while the FY2025 annual figure was -$1.2 million, up 3.77% from the prior year.
• Cash from Financing Activities slipped to -$224879.8 in Q4 2024 per ACIU's latest filing, from -$199677.9 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $46.3 million in Q4 2023 and bottomed at -$991852.5 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $5.5 million across 5 years, with a median of -$126646.0 in 2020.
• Annual changes were most pronounced in 2020 — Cash from Financing Activities slumped 6195.03% — and 2023, when it soared 29609.2%.
• AC Immune's Cash from Financing Activities stood at -$508831.6 in 2020, then surged by 6224.03% to $31.2 million in 2021, then tumbled by 100.5% to -$156741.3 in 2022, then jumped by 29609.2% to $46.3 million in 2023, then sank by 100.49% to -$224879.8 in 2024.
• Business Quant data shows ACIU's Cash from Financing Activities at -$224879.8 in Q4 2024, -$199677.9 in Q3 2024, and $46.3 million in Q4 2023.